Metformin and Alzheimer's disease risk

Comment

Jonathan E Rosenfeld. Am J Psychiatry. 2014 Jan.

. 2014 Jan;171(1):119.

doi: 10.1176/appi.ajp.2013.13091193.

No abstract available

Comment in

Response to Rosenfeld.
Jarskog LF, Stroup TS. Jarskog LF, et al. Am J Psychiatry. 2014 Jan;171(1):119-20. doi: 10.1176/appi.ajp.2013.13091193r. Am J Psychiatry. 2014. PMID: 24399433 No abstract available.

Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.
Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, Lavange L, Ray N, Golden LH, Lieberman JA, Stroup TS; METS Investigators. Jarskog LF, et al. Am J Psychiatry. 2013 Sep;170(9):1032-40. doi: 10.1176/appi.ajp.2013.12010127. Am J Psychiatry. 2013. PMID: 23846733 Free PMC article. Clinical Trial.
Metformin for antipsychotic-related weight gain and metabolic abnormalities: when, for whom, and for how long?
Correll CU, Sikich L, Reeves G, Riddle M. Correll CU, et al. Am J Psychiatry. 2013 Sep;170(9):947-52. doi: 10.1176/appi.ajp.2013.13060771. Am J Psychiatry. 2013. PMID: 24030606 No abstract available.